Abstract
The combination of meropenem with clavulanate has high antimycobacterial activity in vitro against extensively drug-resistant Mycobacterium tuberculosis strains. We report the successful use of this combination in association with linezolid in the management of an advanced extensively drug-resistant tuberculosis disease with complex second-line drug resistance in a 14-year-old teenager.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetamides / administration & dosage
-
Acetamides / adverse effects
-
Acetamides / therapeutic use*
-
Adolescent
-
Antitubercular Agents / administration & dosage
-
Antitubercular Agents / adverse effects
-
Antitubercular Agents / therapeutic use*
-
Clavulanic Acid / administration & dosage
-
Clavulanic Acid / adverse effects
-
Clavulanic Acid / therapeutic use*
-
Extensively Drug-Resistant Tuberculosis / diagnosis
-
Extensively Drug-Resistant Tuberculosis / drug therapy*
-
Female
-
Humans
-
Linezolid
-
Meropenem
-
Oxazolidinones / administration & dosage
-
Oxazolidinones / adverse effects
-
Oxazolidinones / therapeutic use*
-
Thienamycins / administration & dosage
-
Thienamycins / adverse effects
-
Thienamycins / therapeutic use*
-
Treatment Outcome
Substances
-
Acetamides
-
Antitubercular Agents
-
Oxazolidinones
-
Thienamycins
-
Clavulanic Acid
-
Meropenem
-
Linezolid